Latest Regulatory News

Challenger Limited reported a robust 28% increase in statutory net profit after tax to $72 million for 1H25, alongside a 12% rise in normalised net profit and a higher interim dividend. Despite a 12% decline in total life sales, the company’s assets under management grew 12% to $131 billion, reflecting strong operational momentum.

Challenger Limited has reported a robust first half for the 2025 financial year, with net profit after tax climbing 28.2% and an 11.5% increase in its interim dividend, signaling strong momentum in its financial services operations.

Infratil has increased its investment in CDC Data Centres by acquiring an additional 1.58% stake for approximately A$216 million, reinforcing its commitment to the fast-growing digital infrastructure sector.

Reliance Worldwide Corporation Limited has announced an ordinary dividend of USD 0.025 per share for the six months ending December 31, 2024, payable in April 2025. The dividend is unfranked and will be paid in Australian dollars based on a recent exchange rate.

Judo Capital Holdings Limited has released its Basel III Pillar 3 report for the half year ended December 31, 2024, revealing a robust capital position and detailed credit risk exposures that exceed regulatory transparency requirements.

Propell Holdings Limited reported a 75% surge in revenue driven by a rapidly expanding loan book, yet losses more than doubled amid rising impairments. The company is navigating growth challenges while engaging with the ASX on potential delisting.

Maximus Resources Limited has issued a Target's Statement recommending shareholders accept Astral Resources NL's off-market takeover bid, which offers a significant premium and improved liquidity. The offer, valuing Maximus shares at approximately $0.073 each, aims to consolidate gold assets in Western Australia under Astral's larger portfolio.

Cardiex Limited has confirmed to the ASX that it holds no undisclosed information explaining the recent spike in its share price, affirming full compliance with continuous disclosure rules.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

Simonds Group delivered a resilient $13.6 million EBITDA in 1H FY25 amid a soft residential market and announced a strategic acquisition of Dennis Family Homes to fuel future growth.

EV Resources Limited has responded to ASX inquiries confirming the material impact of China's molybdenum export controls and recent high-grade antimony assay results on its securities.

Acorn Capital Investment Fund’s shares were suspended following a late submission of its January 2025 Net Tangible Asset Statement, attributed to human error. The company has assured shareholders the issue is resolved and trading resumed promptly.